Oncologists Embrace BRAF Testing, Coast Through Managed Care With New Melanoma Drugs
Executive Summary
Six-figure pricing in oncology is becoming increasingly common and has raised eyebrows, but a new survey of new melanoma drugs Yervoy and Zelboraf suggests that so far high price is not an obstacle to adoption. So soon after launch, it’s still unclear if one treatment will emerge dominant in first-line treatment.
You may also be interested in...
Oncologists Audition Yervoy And Zelboraf For First-line Roles, With New Combos In Near Sight
Cooperative group plans trial testing Yervoy vs. Zelboraf in first-line metastatic melanoma to help settle the issue of which therapy should come first in BRAF-mutation positive patients. New therapies on the way promise to further complicate decision-making.
Bristol Outperforms In Q3, But Will Dapagliflozin, Apixaban See It Past Plavix?
The big pharma beats analysts' estimates for the third quarter, but all eyes are turned toward its pipeline as the Plavix patent expiry becomes a near-term reality.
Quality Of Biomarkers Questioned Again; Lancet Report Calls For Better Evidence
As personalized medicine shifts from theory to practice, concerns are mounting about whether the evidence behind many biomarkers is sufficient to make pharmacogenomic testing worthwhile – suggesting sponsors should pay careful attention to providing evidence to support use of companion diagnostics.